This company listing is no longer active
RQE1 Stock Overview
Researches, develops, and commercializes cell-based therapies in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ReNeuron Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.034 |
| 52 Week High | UK£0.13 |
| 52 Week Low | UK£0.001 |
| Beta | 0.69 |
| 11 Month Change | 0% |
| 3 Month Change | -11.69% |
| 1 Year Change | -62.22% |
| 33 Year Change | -97.96% |
| 5 Year Change | -98.86% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| RQE1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -2.2% |
| 1Y | -62.2% | -14.4% | 13.3% |
Return vs Industry: RQE1 underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: RQE1 underperformed the German Market which returned 2% over the past year.
Price Volatility
| RQE1 volatility | |
|---|---|
| RQE1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RQE1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RQE1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 26 | n/a | www.reneuron.com |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells.
ReNeuron Group plc Fundamentals Summary
| RQE1 fundamental statistics | |
|---|---|
| Market cap | €2.25m |
| Earnings (TTM) | -€5.91m |
| Revenue (TTM) | €290.24k |
7.7x
P/S Ratio-0.4x
P/E RatioIs RQE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RQE1 income statement (TTM) | |
|---|---|
| Revenue | UK£249.00k |
| Cost of Revenue | UK£3.65m |
| Gross Profit | -UK£3.40m |
| Other Expenses | UK£1.67m |
| Earnings | -UK£5.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -0.089 |
| Gross Margin | -1,367.47% |
| Net Profit Margin | -2,037.35% |
| Debt/Equity Ratio | 0% |
How did RQE1 perform over the long term?
See historical performance and comparison